FTY720 Increases Doxorubicin Sensitivity in Resistant Acute Myeloid Leukemia Cells

Area of Science:

• Hematology
• Pharmacology
• Cancer Biology

Background:

• Chemoresistance is a significant challenge in treating acute myeloid leukemia (AML).
• Resistant AML cells often exhibit reduced intracellular drug accumulation and apoptosis evasion.
• FTY720, a sphingosine-1-phosphate receptor modulator, shows potential antiproliferative and chemosensitizing effects.

Purpose of the Study:

• To investigate if FTY720 enhances doxorubicin sensitivity in doxorubicin-resistant AML cell lines.
• To determine if FTY720 affects drug-efflux transporters and protein kinase B/mechanistic target of rapamycin (PKB/mTOR) signaling.
• To evaluate the combined effects of FTY720 and doxorubicin on AML cell viability and apoptosis.

Main Methods:

• Utilized parental (HL60, K562) and doxorubicin-resistant (HL60/A, K562/A) AML cell lines.
• Assessed cell viability (Cell Counting Kit-8), apoptosis (Annexin V/propidium iodide flow cytometry).
• Quantified intracellular doxorubicin, and analyzed P-glycoprotein, MRP1, PKB/mTOR pathway, and apoptosis proteins (flow cytometry, Western blotting).

Main Results:

• FTY720 demonstrated dose-dependent cytotoxicity and increased doxorubicin sensitivity in resistant AML cells.
• Combined treatment significantly reduced cell viability, increased apoptosis, and enhanced intracellular doxorubicin accumulation.
• FTY720 decreased P-glycoprotein and MRP1 expression, and reduced PKB/mTOR phosphorylation; SC79 partially reversed these effects.

Conclusions:

• FTY720 enhances doxorubicin sensitivity in resistant AML cell lines (HL60/A, K562/A).
• This sensitization is linked to reduced PKB/mTOR signaling, decreased drug-efflux transporter expression, and increased apoptosis.
• Further in vitro and in vivo studies are warranted to validate these findings for clinical application.